RPG Life Sciences Reports Strong Q2 FY27 Results With 16.5% Revenue Growth
RPG Life Sciences Ltd · Press Release · 30 Oct 2026, 3:42 am
RPG Life Sciences Reports Strong Q2 FY27 Results With 16.5% Revenue Growth RPG Life Sciences reported a 16.5% YoY revenue growth to ₹211.6 crore for Q2 FY27 ended 30th Sep'26, crossing the ₹200 crore quarterly milestone. Adjusted EBITDA rose 15.0% YoY to ₹50.1 crore with a 23.7% margin, excluding ₹5.5 crore in one-off API acquisition and restructuring costs (reported EBITDA at ₹44.7 crore). Gross margin expanded 260 bps. Flagship brand Naprosyn surpassed ₹100 crore in sales. During the quarter, the company transferred its API unit to RPG Active Pharma and acquired Actis Generics and Raghava Lifesciences.
Original exchange filing (PDF)
More announcements from RPG Life Sciences Ltd
- Earning call Transcript · 05 Nov 2026
- Audio Recording of Q2FY27 Results Earnings Call held on October 30, 2026 · 31 Oct 2026
- Investor Presentation · 30 Oct 2026
- Amendment to Policy on Related Party Transactions · 30 Oct 2026
- Outcome of Board Meeting held on October 29, 2026. · 30 Oct 2026
- Financial Result for the quarter ended September 30, 2026 · 30 Oct 2026
- Outcome of Board Meeting · 30 Oct 2026
- Outcome of Board meeting · 30 Oct 2026
